Background: Diabetes is a risk factor for atherosclerosis associated with oxidative stress, inflammation and cell proliferation. The purpose of this study was to evaluate arterial choline uptake and its relationship to atherosclerotic inflammation in diabetic and non-diabetic hypercholesterolemic mice. F-FMCH uptake in atherosclerotic plaques was further compared with macrophage infiltration and the plasma levels of cytokines and metabolic markers.
Background
Diabetes is associated with an increased risk of atherosclerotic cardiovascular disease (CVD), and it is common in patients with known or at risk of CVD [1] . Various factors, including increased oxidative stress and subsequent activation of pro-inflammatory pathways, as well as increased cell proliferation in the arterial wall, contribute to accelerated atherosclerosis in diabetes [2] . Inflammation is a key factor in the pathogenesis of atherosclerosis and its complications [3] [4] [5] . Positron emission tomography (PET) with a glucose analogue 2-deoxy-2-[
18 F]-fluoro-d-glucose ( 18 F-FDG) is a feasible method for non-invasive imaging of atherosclerotic plaque inflammation in large arteries. Vascular uptake of 18 F-FDG has also been observed in individuals without symptoms of CVD, in the presence of type 2 diabetes mellitus (T2DM) [6, 7] , metabolic syndrome [8] and obesity [9] . Accumulation of 18 F-FDG in atherosclerotic plaques has been attributed to high glucose uptake in macrophages [4, 10] . In addition to the number of macrophages, 18 F-FDG uptake may reflect their polarization [11, 12] or augmentation of glucose uptake induced by hypoxia [13, 14] . Furthermore, high blood glucose levels in T2DM can diminish 18 F-FDG uptake in atherosclerosis [7] . These factors may complicate the interpretation of 18 F-FDG signal from arteries, especially in diabetic individuals, and therefore, alternative tracers for the quantification of inflammation in atherosclerosis have been investigated [15] [16] [17] .
Choline is taken up into cells by choline transporters, phosphorylated by choline kinase, further metabolized to phosphatidylcholine, and eventually incorporated into the cell membrane or used for lipoprotein assembly. Radiolabeled derivatives of choline have been utilized to detect increased choline uptake in tumor cells [18, 19] and in macrophages at the sites of inflammation [20, 21] . Previous studies have shown increased accumulation of radiolabeled choline derivatives in macrophage-rich atherosclerotic lesions [22, 23] or aortic aneurysms [24] . In asymptomatic patients, 11 C-choline or 18 F-fluoromethylcholine ( 18 F-FMCH) uptake has been detected in large vessels, predominantly in non-calcified atherosclerotic lesions [25, 26] . We hypothesized that the pro-inflammatory phenotype in T2DM is associated with increased choline uptake, thus making 18 F-FMCH a potential tracer for monitoring the progression of atherosclerosis in diabetes.
For this study, we evaluated the uptake of 18 F-FMCH and 18 F-FDG in inflamed atherosclerotic plaques in nondiabetic and diabetic hypercholesterolemic mice [27] . We studied the kinetics and biodistribution of 18 F-FMCH by PET/computed tomography (CT) imaging and in ex vivo tissue samples. Uptake of 18 F-FMCH or 18 F-FDG in atherosclerotic aorta was first quantified by gamma counting and then compared between plaques and adjacent normal vessel wall by autoradiography of aortic tissue sections. Furthermore, 18 F-FMCH uptake was compared with the extent and phenotype of macrophages in atherosclerotic plaques, the plasma levels of inflammatory mediators and metabolic markers.
Methods

Animals and study design
We utilized two hypercholesterolemic mouse models in the study. LDLR −/− ApoB 100/100 mice are deficient in lowdensity lipoprotein (LDL) receptor and express only apolipoprotein B100 (strain #003000, The Jackson Laboratory, Bar Harbor, ME, USA , and additionally represent the characteristics of T2DM (insulin resistance and impaired glucose tolerance in the presence of mildly elevated fasting glucose levels) due to the overexpression of insulin-like growth factor II (IGF-II) in pancreatic beta cells [27, 28] . The mice were fed, for a period of 4 months, with a high-fat diet (TD.88137 adjusted calories diet, Harlan Teklad, 42 % of calories from fat, 0.2 % total cholesterol, no sodium cholate, Harlan Laboratories, Madison, WI, USA) to accelerate atherosclerosis development.
Accumulation of ApoB 100/100 mice (n = 11/group) at the age of 6-7 months, after 4 months on high-fat diet. For comparison, age-and gender-matched groups of mice (n = 11-12/group) were similarly studied using 18 F-FDG. Healthy C57BL/6N mice fed with normal chow diet (age 8 months, n = 13) were studied with 18 F-FMCH as controls. The characteristics of the study animals are shown in Table 1 . Data on additional 8-10-month-old IGF-II/ LDLR −/− ApoB 100/100 mice fed with a longer high-fat diet are shown in the Additional file 1.
All the animal experiments were performed in accordance with the relevant European Union Directive and approved by the National Animal Experiment Board in Finland and the Regional State Administrative Agency for Southern Finland (Licence numbers ESAVI/1583/04.10.03/2012 and ESAVI/2163/04.10.07/2015). The mice were housed in standardized conditions with a 12/12 h dark/light cycle and they had access to water and food ad libitum. The studies were performed under isoflurane anesthesia. The mice were fasted for 4 h before the 18 F-FDG injection to standardize plasma glucose level. Since fasting had not shown any detectable effect on choline uptake in previous studies [29] or in our pre-study (see Additional file 1), the mice were not fasted before the 18 F-FMCH injection.
Radiotracers
The 18 F-FMCH batches were purchased from MAP Medical Technologies Oy (Helsinki, Finland). The radiochemical purity exceeded 95 % in every batch. 18 F-FDG was synthesized in the radiopharmaceutical laboratory of Turku PET Centre. 18 F-FMCH in vivo stability was assessed by radio-HPLC (see Additional file 1).
In vivo PET/CT imaging
In order to study the distribution kinetics of ApoB 100/100 mice were imaged with Inveon Multimodality small animal PET/CT scanner (Siemens Medical Solutions, Knoxville, TN, USA). The mice were injected with approximately 6 MBq of 18 F-FMCH via tail vein and a dynamic 30-minute PET was started at the same time. After PET imaging, 100-150 µl of intravenous contrast agent (eXia 160XL, Binitio Biomedical, Ottawa, Ontario, Canada) was injected and a high-resolution CT imaging was performed. The CT acquisition consisted of 270 projections with the exposure time of 1250 ms for a full 360° rotation. X-ray voltage was 80 kVp and anode current 500 µA.
PET data acquired in a list mode were iteratively reconstructed with a 2-dimensional ordered-subsets expectation maximization algorithm into 30 × 10 s and 15 × 60 s frames. A reconstructed image had 128 × 128 × 159 matrix size with a pixel size of 0.776 × 0.776 × 0.796 mm. CT images were reconstructed with a filtered back-projection algorithm (pixel size 0.094 × 0.094 × 0.094 mm). In vivo PET and CT images were co-registered and dynamic PET data was analyzed with Carimas 2.8 software (Turku PET Centre, Turku, Finland). Regions of interest (ROI) were defined in selected tissues based on the high-resolution CT in order to obtain time-activity curves. The ROI for blood pool was located in vena cava.
Ex vivo PET imaging
For a subset of mice studied with 
Blood sampling and ex vivo tracer distribution measurement
The mice were i.v. injected with 10-11 MBq of 18 F-FMCH or 18 F-FDG and killed with cardiac puncture and cervical dislocation under deep anesthesia at 20 or 90 min postinjection, respectively. The time points were chosen based on tracer-specific kinetics [23, 30] . Approximately 50 µl of blood was measured for radioactivity. The rest of the blood sample was centrifuged and the separated plasma was stored at −70 °C for further analyses. To assess the distribution of the radiotracers, the aortas and selected other tissues were excised, weighed and measured using a gamma counter (1480 Wizard 3″; Perkin Elmer/Wallac, Turku, Finland or Triathler 3″, Hidex, Turku, Finland). Radioactivity concentration was decay-corrected to the injection time and expressed as percentage of injected radioactivity dose per gram of tissue (% IA/g).
Autoradiography of aortic sections
The distribution of 18 F-FMCH and 18 F-FDG in the aortas of mice was further studied by autoradiography. The aortas were frozen in ice-cold isopentane, cut into sequential 20-and 8-µm sections and apposed to an imaging plate for digital autoradiography. After an overnight exposure, the plates were scanned with Fuji Analyzer BAS-5000 (Fuji, Tokyo, Japan; internal resolution 25 μm) and the sections were stored at −70 °C. The autoradiography analysis was performed with TINA 2.1 software (Raytest Isotopemessgeräte, GmbH, Straubenhardt, Germany). In the autoradiographs of the 20-µm sections, ROIs were defined in plaques (excluding calcifications), adjacent histologically normal vessel wall and vessel-surrounding adventitia, based on hematoxylin-eosin staining (H&E). Background counts were subtracted and results expressed as photo-stimulated luminescence (PSL)/mm 2 . The values were normalized for injected radioactivity, mouse weight and radioactivity decay during exposure. On average, 50 ROIs for plaque, 25 for wall and 27 for adventitia per animal were analyzed. For atherosclerotic mice, plaque-to-wall uptake ratio was calculated.
Histology and immunohistochemistry
The 20-µm aortic sections were stained with H&E for histological evaluation. In order to assess the plaque inflammation, the 8-µm sections were immunostained for macrophages with anti-Mac-3 antibody (clone M3/84, 1:5000, BD Pharmingen, Franklin Lakes, NJ, USA) as described before [31] . Additional 8-µm sections were stained with anti-Ki-67 antibody (clone TEC-3, M7249, 1:1000, Dako, Glostrup, Denmark) to detect cell proliferation. Aortic roots (n = 8-9/group) were formalin-fixed, paraffin-embedded, and cut into serial 5-µm sections for the histological comparison of the characteristics of atherosclerosis in LDLR −/− ApoB 100/100 and IGF-II/LDLR −/− ApoB 100/100 mice. The sections were stained with Movat's pentachrome to assess the plaque burden, expressed as intima-to-media ratio (IMR). Macrophages were stained with anti-Mac-3 antibody. Additionally, sections were stained with anti-inducible nitric oxide synthase (iNOS) or anti-mannose receptor C-type 1 (MRC-1) antibodies to detect M1 (pro-inflammatory) and M2 (anti-inflammatory) polarized macrophages, respectively. Immunohistochemical staining for scavenger receptor CD36, involved in the atherogenesis, was also performed. The staining protocols are described in Additional file 1 and the analyses in [32] .
Comparison of
18
F-FMCH uptake and macrophages in plaques
To compare 18 F-FMCH uptake and inflammation (amount of macrophages), a subset of diabetic mice (n = 8) was studied. In autoradiographs, ROIs were defined in plaque areas showing no or only few macrophages and areas with macrophage infiltration. Based on the areal percentage of Mac-3-positive staining as quantified with ImageJ software (Fiji, National Institutes of Health, Bethesda, MD, USA), the plaque areas were classified as representing low, intermediate or high macrophage density. 18 F-FMCH uptake in the areas was expressed as PSL/mm 2 as described above. 
Correlation of
18
F-FMCH plaque uptake and plasma biomarkers
Statistical analyses
Results are expressed as mean ± SEM unless otherwise specified. Statistical analyses were conducted with IBM SPSS Statistics 21 (IBM Corp., Armonk, NY, USA). The comparisons between two groups were made using independent samples t test, and the comparisons between multiple groups using one-way ANOVA with Tukey or Tamhane correction. Paired t-test was applied when comparing uptake between different tissues in the same animals. The correlations were assessed with Pearson's coefficient (r). The p values <0.05 were considered statistically significant.
Results
Total cholesterol levels were similar in non-diabetic (LDLR ) mice (31 ± 4.3 and 36 ± 12 mmol/l, respectively), as were also the fasting glucose levels (7.8 ± 1.0 and 9.1 ± 3.1 mmol/l, respectively). There was a tendency towards higher blood levels of insulin, C-peptide and IL-6 in diabetic mice (Additional file 1: Table S3 ). The total cholesterol was significantly lower in C57BL/6N control than in the hypercholesterolemic mice (1.8 ± 0.3, p < 0.001).
The aortas of both non-diabetic and diabetic hypercholesterolemic mice showed extensive atherosclerosis, mainly fibroatheroma-type lesions with large, confluent areas of Mac-3-positive macrophages, whereas no atherosclerosis was observed in control mice (Fig. 1) . All plaques showed positivity for iNOS and MRC-1, indicating M1 and M2 polarized macrophages, respectively. The scavenger receptor CD36 co-localized with the macrophage-positive areas of plaques, while only occasional Ki-67 positive cells were observed. Occasional plaque calcifications were seen in 60 % of non-diabetic and 73 % of diabetic mice. The plaques of non-diabetic and diabetic mice showed no difference in any of the measured histological characteristics (Table 2 ). F-FMCH PET imaging revealed focal areas of high tracer uptake in the aortic arch of atherosclerotic mice, as compared with the lower and homogeneous uptake in the aortas of healthy control mice. PET images of the aorta and the heart are shown in Fig. 2c .
In vivo PET/CT imaging
Uptake of
18
F-FMCH in diabetic atherosclerosis
The uptakes of 18 F-FMCH in aorta and other tissues are shown in Table 3 . Aortic 18 F-FMCH uptake was higher in diabetic than non-diabetic atherosclerotic mice or healthy controls (p = 0.025 and p < 0.001, respectively). The remaining blood radioactivity was lower in diabetic than non-diabetic mice (p = 0.0050), and thus, the aortato-blood ratio was higher (p = 0.017). The radioactivity concentrations in urine also tended to be lower in diabetic than non-diabetic mice (p = 0.058).
Autoradiography showed strong and clearly delineated accumulation of 18 F-FMCH in atherosclerotic plaques in both diabetic and non-diabetic mice ( Fig. 3 ; Table 4 ). 18 F-FMCH uptake was significantly higher in plaques than in normal vessel wall or adventitia. In the normal vessel wall, uptake of 18 F-FMCH was similar in non-diabetic and diabetic atherosclerotic mice and in controls. 18 F-FMCH uptake in plaques was higher in diabetic mice, but the plaque-to-wall ratios were similar in non-diabetic and diabetic mice (2.5 ± 0.10 and 2.6 ± 0.085, p = 0.19). 
Comparison of
18
F-FMCH plaque uptake and macrophages in immunohistochemistry
The uptakes of 
Correlation of
18
F-FMCH plaque uptake and plasma biomarkers
The average 
F-FMCH
The distribution of 18 F-FMCH autoradiographs of the mouse aortic arch are shown in Fig. 3 . Average plaque-to-wall ratios were similar between 18 F-FMCH and 18 F-FDG in non-diabetic mice, but significantly higher with 18 F-FMCH than 18 F-FDG in diabetic mice (Fig. 6) . Gamma counting showed that the absolute uptake of 18 F-FMCH in the whole aorta was lower than that of 18 F-FDG in both diabetic (2.0 ± 0.17 vs. 4.7 ± 0.41 % IA/g, p < 0.001) and non-diabetic mice (1.5 ± 0.11 vs. 5.0 ± 0.40, p < 0.001). However, the aorta-to-blood ratios of the tracers were similar in diabetic mice (3.9 ± 0.65 vs. 3.6 ± 0.49, p = 0.70), whereas in non-diabetic mice, the ratio was lower with 18 F-FMCH than with 18 F-FDG (1.6 ± 0.14 vs. 4.9 ± 0.68, p < 0.001). The uptake of 18 F-FMCH in myocardium was, however, lower than that of 18 F-FDG in both diabetic (8.4 ± 0.80 vs. 65 ± 8.0 % IA/g, p < 0.001) and non-diabetic (6.8 ± 0.44 vs. 49 ± 4.7, p < 0.001) mice, resulting in a higher aorta-to-myocardium ratio (Fig. 6 ).
Discussion
The uptake of the PET tracer 18 F-FMCH is increased in the atherosclerotic aorta of mice with T2DM. The uptake in atherosclerotic plaques was associated with the amount of Mac-3 positive macrophages in plaques, as well as the plasma levels of total cholesterol, certain metabolic markers and cytokines. In comparison with 18 F-FDG, 18 F-FMCH provided similar or higher targetto-background ratios between atherosclerotic plaques and the normal vessel wall, as well as aorta and blood or myocardium in diabetic mice. These results indicate that T2DM is associated with increased uptake of choline in atherosclerosis and that 18 F-FMCH may be useful for the evaluation of vascular inflammation in diabetes.
Studies using 18 F-FDG PET have revealed subclinical vascular inflammation in patients with abnormal glucose metabolism [6] [7] [8] . More recent studies have indicated contribution of pericardial and visceral fat to vascular inflammation [9, 33] . Molecular imaging of vascular inflammation is a potential tool to study mechanisms of atherosclerosis, effects of therapies and eventually risk of CVD in high-risk individuals, such as those with diabetes [4] .
The LDLR −/−
ApoB 100/100 mouse model is a well characterized and widely utilized model of hypercholesterolemia and atherosclerosis. Abnormalities in apolipoprotein E (ApoE) rarely contribute to human hypercholesterolemia, and therefore, the LDLR −/− mouse model better mimics the human disease. The addition of the gene modification leading to the expression of only apolipoprotein B100 on the LDLR −/− background further raises the cholesterol level and amplifies the progression of atherosclerosis [28] . Despite the only mildly elevated fasting glucose levels, the IGF-II/LDLR , the diabetic mice represent accelerated development of macrovascular complications, including more calcified, less organized and more complex lesions with higher IL-6 expression [27, 34] . Our findings of elevated plasma insulin, C-peptide and IL-6 levels are in line with the T2DM phenotype. Taken together, these data suggest a more pro-inflammatory milieu in the diabetic IGF-II/LDLR mice.
The 18 F-FMCH uptake was increased in the atherosclerotic aorta of diabetic mice as compared with nondiabetic mice. In addition, the correlations between the 18 F-FMCH plaque uptake and the plasma C-peptide, insulin and leptin levels support the association of the uptake to diabetic phenotype. In both diabetic and non-diabetic mice, the plaques represented similar amounts of M1 and M2 polarized macrophages and also scavenger receptor CD36. Therefore, the higher 18 F-FMCH uptake in the inflamed plaques may reflect increased choline transport [23] and metabolism in the macrophages. Interestingly, 18 F-FMCH seems to have an enhanced cellular intake in diabetic mice, since the tracer tends to be more cleared from the blood and less excreted in the urine at the 20-minute time point as compared with non-diabetic mice. The absolute uptake of 18 F-FMCH was higher in the aortas of diabetic mice as compared with non-diabetic mice, as was also the aorta-to-blood uptake ratio due to lower remaining tracer in circulation. Because blood will always be included in the ROI due to the limited resolution of PET images, high aorta-to-blood ratio is a good property for the in vivo imaging of tracer uptake in atherosclerotic plaques.
In the current study, the plaque-to-wall uptake ratio of 18 F-FMCH (on average 2.6) was within the same range as that of 11 C-choline (2.3) or 18 F-fluorocholine (3.5) in previous studies in mice [22, 23] . In line with previous F-FMCH uptake and the risk of atherosclerosis. Recent reports, however, suggest that PLTP activity is inversely correlated with carotid artery disease and linked with PON-1 [43] , and that PON-1 is regarded as an atheroprotective enzyme [44, 45] .
In previous studies, arterial uptake of 18 F-FDG or 11 C-choline did not typically co-localize with calcifications seen on CT supporting the concept that inflammation and calcification occur at different stages of atherosclerosis [4, 25] . Our findings with 18 F-FMCH suggest the same pattern since vascular tracer uptake was lower in 9-month-old mice (% IA/g 1.7, plaque-to-wall ratio 2.2, see Additional file 1) than in 6-month-old mice (% IA/g 2.0, plaque-to-wall ratio 2.6), despite more extensive vascular calcification (calcifications in all animals at the age of 9 months vs. in 73 % of animals at the age of 6 months), but less macrophages. Although 18 F-FDG is the most commonly used tracer for atherosclerotic plaque imaging, the high physiological tracer uptake in the myocardium has limited its application for imaging coronary artery inflammation, although it is possible to reduce the uptake by means of metabolic interventions [4] . In this study, the myocardial uptake was lower for 18 F-FMCH than for 18 F-FDG, and, moreover, the myocardial uptake of 11 C-choline has been negligible in patients [25] , thus promoting the feasibility of 18 F-FMCH in coronary artery imaging. As compared with 18 F-FDG, 18 F-FMCH showed superior plaque-towall ratio, equal aorta-to-blood ratio and higher aortato-myocardium ratio in the diabetic mice, suggesting potential for monitoring atherosclerosis progression in diabetes.
There are some limitations in our study. The reasons for insulin resistance in our mouse model are not fully understood, the model does not represent the full phenotypic spectrum of T2DM in patients, and our findings need to be verified in clinical studies [46] . The feasibility of 18 F-FMCH for detecting atherosclerotic plaque inflammation by in vivo PET imaging remains to be investigated because, in our study, only young IGF-II/LDLR −/− ApoB 100/100 mice were imaged with PET/ CT and it was not possible to visualize the small plaques existing at the young age. Taken together, our findings support the concept of utilizing choline-based radiopharmaceuticals in the imaging of inflammation in diabetic atherosclerosis, but further in vivo imaging studies in patients are needed to proof this. F-FMCH shows a significantly higher aorta-to-myocardium ratio in both mouse strains
